HC Wainwright Predicts Cingulate FY2025 Earnings

Cingulate Inc. (NASDAQ:CING) – HC Wainwright issued their FY2025 earnings per share (EPS) estimates for Cingulate in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($2.97) per share for the year. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share.

Other equities analysts have also recently issued research reports about the company. Roth Mkm started coverage on Cingulate in a report on Friday, January 10th. They set a “buy” rating and a $12.00 price target for the company. Roth Capital raised shares of Cingulate to a “strong-buy” rating in a report on Friday, January 10th. Finally, Maxim Group raised shares of Cingulate from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th.

Cingulate Stock Performance

Shares of Cingulate stock opened at $4.55 on Friday. Cingulate has a twelve month low of $1.80 and a twelve month high of $58.32. The business has a 50-day moving average price of $4.59 and a 200-day moving average price of $4.53.

Cingulate (NASDAQ:CING) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.22) by $0.39.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cingulate stock. AlphaMark Advisors LLC lifted its stake in shares of Cingulate Inc. (NASDAQ:CING) by 50,000.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,010 shares of the company’s stock after acquiring an additional 5,000 shares during the quarter. AlphaMark Advisors LLC owned approximately 0.16% of Cingulate worth $25,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 41.31% of the company’s stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.